BACKGROUND: Corticosteroids have been invariant transplant immunosuppressives with numerous adverse effects. We previously reported 6-month results in 10 patients using extended daclizumab induction to safely eliminate steroid use in pediatric renal transplantation. This expanded pilot series discusses immunosuppression dosing modification to further minimize drug toxicity without sacrificing regimen efficacy. METHODS:Fifty-seven pediatric renal transplant recipients were enrolled in the pilot steroid-free protocol. Extended daclizumab induction, tacrolimus, and mycophenolate mofetil (MMF) were intended maintenance drugs. Fourteen patients were equal to or younger than 5 years, and 43 patients were older than 5 years of age at transplantation. There were seven protocol breaks. Study patients underwent serial protocol transplant biopsies (n=246), and serum daclizumab and mycophenolic acid (MPA) trough levels were evaluated. In this efficacy study, controls were 50 historical-matched steroid-based children receiving tacrolimus with 100% 2-year graft survival and without delayed graft function. RESULTS: Mean follow-up was 20 (range, 4.5-41) months with 98% overall graft and patient survival. At 1 year of analysis, steroid-free recipients showed significant improvements for clinical acute rejection (8%), graft function, hypertension, and growth, without increased infectious complications. Leukopenia, anemia, and allograft nephrotoxicity were addressed by solely decreasing MMF and tacrolimus dosing and/or by replacing MMF with sirolimus, without increasing acute rejection. Early daclizumab levels of more than 5 microg/mL were observed for the first time in children of all ages. CONCLUSIONS:Pediatric renal transplantation is safe without steroids. Daclizumab first-dose doubling and extended use for 6 months replaces steroids effectively without evidence of overimmunosuppression and may be the pivotal cause for the reduced acute rejection seen in this trial. This pilot study provides preliminary data to test this protocol in a prospective, multicenter randomized study.
RCT Entities:
BACKGROUND: Corticosteroids have been invariant transplant immunosuppressives with numerous adverse effects. We previously reported 6-month results in 10 patients using extended daclizumab induction to safely eliminate steroid use in pediatric renal transplantation. This expanded pilot series discusses immunosuppression dosing modification to further minimize drug toxicity without sacrificing regimen efficacy. METHODS: Fifty-seven pediatric renal transplant recipients were enrolled in the pilot steroid-free protocol. Extended daclizumab induction, tacrolimus, and mycophenolate mofetil (MMF) were intended maintenance drugs. Fourteen patients were equal to or younger than 5 years, and 43 patients were older than 5 years of age at transplantation. There were seven protocol breaks. Study patients underwent serial protocol transplant biopsies (n=246), and serum daclizumab and mycophenolic acid (MPA) trough levels were evaluated. In this efficacy study, controls were 50 historical-matched steroid-based children receiving tacrolimus with 100% 2-year graft survival and without delayed graft function. RESULTS: Mean follow-up was 20 (range, 4.5-41) months with 98% overall graft and patient survival. At 1 year of analysis, steroid-free recipients showed significant improvements for clinical acute rejection (8%), graft function, hypertension, and growth, without increased infectious complications. Leukopenia, anemia, and allograft nephrotoxicity were addressed by solely decreasing MMF and tacrolimus dosing and/or by replacing MMF with sirolimus, without increasing acute rejection. Early daclizumab levels of more than 5 microg/mL were observed for the first time in children of all ages. CONCLUSIONS: Pediatric renal transplantation is safe without steroids. Daclizumab first-dose doubling and extended use for 6 months replaces steroids effectively without evidence of overimmunosuppression and may be the pivotal cause for the reduced acute rejection seen in this trial. This pilot study provides preliminary data to test this protocol in a prospective, multicenter randomized study.
Authors: Li Li; Persis Wadia; Rong Chen; Neeraja Kambham; Maarten Naesens; Tara K Sigdel; David B Miklos; Minnie M Sarwal; Atul J Butte Journal: Proc Natl Acad Sci U S A Date: 2009-02-27 Impact factor: 11.205
Authors: Avram Z Traum; Tatsuo Kawai; Joseph P Vacanti; David H Sachs; A Benedict Cosimi; Joren C Madsen Journal: Pediatrics Date: 2008-06 Impact factor: 7.124
Authors: Jonathan L Berkowitz; John E Janik; Donn M Stewart; Elaine S Jaffe; Maryalice Stetler-Stevenson; Joanna H Shih; Thomas A Fleisher; Maria Turner; Nicole E Urquhart; Gilian H Wharfe; William D Figg; Cody J Peer; Carolyn K Goldman; Thomas A Waldmann; John C Morris Journal: Clin Immunol Date: 2014-09-28 Impact factor: 3.969
Authors: Pauline Lancia; Tiphaine Adam de Beaumais; Valéry Elie; Florentine Garaix; Marc Fila; François Nobili; Bruno Ranchin; Pascale Testevuide; Tim Ulinski; Wei Zhao; Georges Deschênes; Evelyne Jacqz-Aigrain Journal: Pediatr Nephrol Date: 2018-02-04 Impact factor: 3.714
Authors: Rong Chen; Tara K Sigdel; Li Li; Neeraja Kambham; Joel T Dudley; Szu-Chuan Hsieh; R Bryan Klassen; Amery Chen; Tuyen Caohuu; Alexander A Morgan; Hannah A Valantine; Kiran K Khush; Minnie M Sarwal; Atul J Butte Journal: PLoS Comput Biol Date: 2010-09-23 Impact factor: 4.475
Authors: Abanti Chaudhuri; Mikki Ozawa; Matthew J Everly; Robert Ettenger; Vikas Dharnidharka; Mark Benfield; Robert Mathias; Anthony Portale; Ruth McDonald; William Harmon; David Kershaw; V Matti Vehaskari; Elaine Kamil; H Jorge Baluarte; Bradley Warady; Li Li; Tara K Sigdel; Szu-chuan Hsieh; Hong Dai; Maarten Naesens; Janie Waskerwitz; Oscar Salvatierra; Paul I Terasaki; Minnie M Sarwal Journal: J Am Soc Nephrol Date: 2013-02-28 Impact factor: 10.121
Authors: Arthur J Matas; Raja Kandaswamy; Abhinav Humar; William D Payne; David L Dunn; John S Najarian; Rainer W G Gruessner; Kristen J Gillingham; Lois E McHugh; David E R Sutherland Journal: Ann Surg Date: 2004-09 Impact factor: 12.969